GCG and metabolic dysfunction-associated steatohepatitis: A prominent example is the class of GLP-1 receptor agonists, which resolve NASH in a significant proportion of patients—likely through combined weight-reduction and anti-inflammatory actions—thereby linking gut–pancreas incretin signaling with gut–liver metabolic benefits [160].